Inventiva Sa

Inventiva Sa EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Inventiva Sa (IVA) as of Oct 18, 2026 is -5.12. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -7.73 — a change of -33.79% (higher).

EV/FCF

-5.12

YoY

-33.79%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Inventiva Sa is 2025 -5.12 . EV/FCF (Enterprise Value to Free Cash Flow) of Inventiva Sa was 2024 -7.73 . It decreases by -33.79% higher compared to the previous year.

The Inventiva Sa EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-18.84 USD
Jan 1, 2019
-23.60 USD
Jan 1, 2020
-19.87 USD
Jan 1, 2021
-13.14 USD
Jan 1, 2022
-14.44 USD
Jan 1, 2023
-8.76 USD
Jan 1, 2024
-7.73 USD
Jan 1, 2025
-5.12 USD
The Inventiva Sa EV/FCF history
YEAREV/FCFYoY
-5.12-33.79%
-7.73-11.74%
-8.76-39.32%
-14.44+9.88%
-13.14-33.87%
-19.87-15.80%
-23.60+25.27%
-18.84-49.54%
-37.34-17.77%
-45.41-1.24%
-45.98+6.78%
-43.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventiva Sa Stock analysis

What does Inventiva Sa do? Inventiva Sa is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company focuses on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases. Inventiva Sa is listed on the stock market with the ticker IVA and ISIN US46124U1079. It went public through an IPO on July 10, 2020. The company has 77 employees and operates within the Health Care sector. Its primary product development includes Lanifibranor, a peroxisome proliferator-activated receptor agonist currently in the NATiV3 Phase 3 clinical trial for treating adult patients with MASH. Additionally, the company is developing Odiparcil for mucopolysaccharidoses and has a pre-clinical program targeting TGF-ß for idiopathic pulmonary fibrosis. Inventiva Sa's website is https://inventivapharma.com. The company operates internationally, with its headquarters located in Daix, France. It is incorporated under French law, though the founding year is not specified in the provided information. The company's research and development efforts are centered on innovative therapeutic approaches for serious medical conditions. Inventiva Sa is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventiva Sa stock

EV/FCF (Enterprise Value to Free Cash Flow) of Inventiva Sa is -5.12 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Inventiva Sa changed from -7.73 to -5.12, representing a -33.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Inventiva Sa since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Inventiva Sa with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Inventiva Sa

All Key Metrics — Inventiva Sa